**Fig-1S: Comparative analysis of BCR-ABL1 levels and miRNA-126 expression levels in CML patients before and after imatinib treatment.**



The miR-126 and miR-122 expression levels at the time of presentation i.e., before the start of imatinib therapy was 0.20 fold and 0.22 fold respectively which correspondingly increased to 5.55 fold and 3.07 fold after the six months of initiation of imatinib therapy. Therefore, expression of both the miRNAs was found to be increased significantly in CML patients after imatinib therapy by 26.25 fold and 13.91 fold for miR-126 and miR-122 respectively.

**Fig-2S: Comparative analysis of BCR-ABL1 levels and miRNA-122 expression levels in CML patients before and after imatinib treatment.**



The miR-126 and miR-122 expression levels were analysed and compared among the patients of the three response categories and it was observed that miR-122 expression levels were not conclusive as no definitive pattern was seen in the three categories which did not allow us to reach any conclusive observation on miR-122 expression patterns in concert with imatinib treatment. However, miR-126 expression exhibited a statistically significant and progressive increase among CML patients with optimal response followed by patients in warning and failure (figure 2).